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License 4.0 (CC BY-NC).ASXL1 interacts with the cohesin complex to maintain
chromatid separation and gene expression
for normal hematopoiesis
Zhaomin Li,1,2 Peng Zhang,1,2 Aimin Yan,1 Zhengyu Guo,3 Yuguang Ban,1 Jin Li,3 Shi Chen,1,2
Hui Yang,1,2 Yongzheng He,4 Jianping Li,1,2 Ying Guo,1,2 Wen Zhang,1,2 Ehsan Hajiramezanali,3
Huangda An,1,2 Darlene Fajardo,1,2 J. William Harbour,1 Yijun Ruan,5 Stephen D. Nimer,1,2,6
Peng Yu,3 Xi Chen,1,7* Mingjiang Xu,1,2* Feng-Chun Yang1,2*ASXL1 is frequently mutated in a spectrum of myeloid malignancies with poor prognosis. Loss of Asxl1 leads to
myelodysplastic syndrome–like disease in mice; however, the underlying molecular mechanisms remain un-
clear. We report that ASXL1 interacts with the cohesin complex, which has been shown to guide sister chroma-
tid segregation and regulate gene expression. Loss of Asxl1 impairs the cohesin function, as reflected by an
impaired telophase chromatid disjunction in hematopoietic cells. Chromatin immunoprecipitation followed
by DNA sequencing data revealed that ASXL1, RAD21, and SMC1A share 93% of genomic binding sites at
promoter regions in Lin−cKit+ (LK) cells. We have shown that loss of Asxl1 reduces the genome binding of
RAD21 and SMC1A and alters the expression of ASXL1/cohesin target genes in LK cells. Our study underscores
the ASXL1-cohesin interaction as a novel means to maintain normal sister chromatid separation and regulate
gene expression in hematopoietic cells.INTRODUCTION
ASXL1 (additional sex combs like 1) gene mutations frequently occur
in a spectrum of myeloid malignancies, including myelodysplastic
syndrome (MDS), chronic myelomonocytic leukemia (CMML), my-
eloproliferative neoplasms (MPNs), and acute myeloid leukemia
(AML) (1–4). ASXL1 mutation is a poor prognostic marker for
MDS, CMML, andAML (5–7), suggesting an important role ofASXL1
mutations in disease initiation and progression. The ASXL1 gene en-
codes ASXL1, one of the polycomb group proteins. These proteins are
necessary for the maintenance of stable repression of homeotic genes
and other gene loci (8–10). We and others have reported that loss of
Asxl1 leads to the development of MDS-like diseases in mice, which
can progress to bone marrow (BM) failure or MPN (11, 12). ASXL1
has also been shown to regulate the self-renewal and differentiation
of mesenchymal stromal cells and erythropoiesis (13, 14). In addi-
tion, loss of Asxl1 in hematopoietic stem cells (HSCs)/hematopoietic
progenitor cells (HPCs) reduces global levels of histone H3 lysine 27
trimethylation (H3K27me3) and H3K4me3, and alters the expres-
sion of genes implicated in apoptosis (11).
Cohesin is a multiple-subunit protein complex that is highly con-
served in mammalian cells (15). The cohesin complex consists of four
major subunits: RAD21, SMC1A, SMC3, and STAG1/STAG2 (16, 17).
The core cohesin proteins form a triangular ring, which embraces sis-
ter chromatids and prevents their premature separation (18, 19). Be-sides its major function in sister chromatid cohesion, the cohesin
complex participates in many other cellular processes, such as tran-
scriptional regulation through long-range cis interactions (20–26). Re-
cently, clinical studies have discovered recurrent mutations or
deletions in the cohesin genes in a variety of myeloid malignancies,
including MDS, AML, CMML, and chronic myelogenous leukemia
(16, 27, 28). Furthermore, cohesin mutations occur in a mutually ex-
clusive manner (16, 29, 30). A more recent study by Merkenschlager
and Odom (31) suggests that cohesin associates with enhancers, pro-
moters, and sites defined by CTCF (CCCTC-binding factor) binding
to form regulated networks of long-range interactions that can pro-
mote cell type–specific transcriptional programs.
Here, we report that ASXL1 interacts with the core proteins of the
cohesin complex. Chromatin immunoprecipitation followed by DNA
sequencing (ChIP-seq) analysis revealed a significant overlap between
the ASXL1, RAD21, and SMC1A binding sites on the genome, mainly
located at the promoter regions of genes. Loss of Asxl1 decreased
RAD21 and SMC1A occupancy on the genome and altered expression
of their target genes. Deletion of Asxl1 results in a significantly higher
frequency of impaired telophase chromatid disjunction in hematopoie-
tic cells, congruent with the previous finding by Díaz-Martínez et al.
(32); the silencing of RAD21 leads to the nuclear bridging of HeLa cells.
Collectively, these data demonstrate a novel biological function of
ASXL1 in transcriptional regulation via interaction with cohesin
complex proteins, in addition to themaintenance of normal chromatid
separation. These findings provide strong evidence thatASXL1 is essen-
tial for the maintenance of gene expression and for preventing dysplas-
tic morphology formation via cohesin complex in HSC/HPCs.RESULTS
ASXL1 interacts with cohesin complex proteins
Located in the nucleus and capable of regulating gene expression,
ASXL1 should exert its function in concert with its interacting part-
ners. To identify functionalASXL1 interacting proteins, we performed1 of 11
SC I ENCE ADVANCES | R E S EARCH ART I C L Eprotein affinity purification using an anti-FLAG antibody (fig. S1A)
and nuclear extracts prepared from human embryonic kidney
(HEK) 293T cells engineered to overexpress FLAG-tagged ASXL1
(fig. S1B). The ASXL1 interacting proteins were identified by liquid
chromatography–tandem mass spectrometry (LC-MS/MS) analysis
(table S1). We found that ASXL1 associates with all core members
of the cohesin complex, including RAD21, SMC1A, SMC3, STAG1,Li et al. Sci. Adv. 2017;3 : e1601602 20 January 2017and STAG2 (Fig. 1A). Co-immunoprecipitation (co-IP) andWestern
blotting analyses revealed that ASXL1 interacts with SMC1A, SMC3,
andRAD21 in FLAG-ASXL1 overexpressingHEK293T cells (Fig. 1B).
Furthermore, reciprocal IP confirmed the interaction of ASXL1 with
SMC1A, SMC3, andRAD21 in FLAG-ASXL1overexpressingHEK293T
cells (Fig. 1, C to E). To study the endogenous interaction between
ASXL1 and cohesin proteins, we carried out co-IP using primary BMA
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Fig. 1. ASXL1 associateswith cohesin complexproteins. (A) Table of the most relevant proteins identified by LC-MS/MS in the affinity purification of ASXL1-associated
proteins using FLAG-ASXL1 overexpressing HEK293T cells. Spectral counts (unique and total) for each interacting protein are shown. (B to E) Reciprocal IP and Western
blotting confirmed interaction of ASXL1 with SMC1A, SMC3, and RAD21 in nuclear fraction derived from HEK293T cells transfected with pcDNA3.1+ (Vec) or FLAG-
tagged ASXL1 (ASXL1). Nuclear extractions were subjected to IP using indicated antibodies against FLAG (B), SMC1A (C), SMC3 (D), or RAD21 (E). IB, immunoblot.
(F) Western blot shows the endogenous interaction between ASXL1 and SMC1A, SMC3, and RAD21 in BM cells of WT mice. IgG, immunoglobulin G. (G) Gel filtration
analysis of nuclear extracts from FLAG-ASXL1 overexpressing cells. ASXL1 and the cohesin complex were coeluted from a Superose 6 HR gel filtration column, as
analyzed by Western blotting. The numbers over the lanes represent the eluted fraction numbers.2 of 11
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endogenous SMC1A, SMC3, and RAD21 (Fig. 1F and fig. S1C).
To determine whether ASXL1 and cohesin complex members co-
exist in a complex, we fractionated the nuclear extracts of ASXL1
overexpressing HEK293T cells on size exclusion chromatography.
Western blot analysis showed that ASXL1 coeluted with SMC1A,
SMC3, and RAD21 in high–molecular weight fractions (Fig. 1G),
suggesting that ASXL1 is part of a large multiprotein complex that
includes cohesin complex proteins.
To map the interacting region of ASXL1 with the cohesin com-
plex, we generated a series of constructs that encode various FLAG-Li et al. Sci. Adv. 2017;3 : e1601602 20 January 2017tagged ASXL1 truncations (Fig. 2A). We then overexpressed each of
the ASXL1 truncates inHEK293T cells and performedWestern blots
on the anti-FLAG IP. ASXL1 full-length amino acids 1 to 1010 and
1 to 587, but not amino acids 1 to 420, successfully pulled down
RAD21, SMC1A, and SMC3 (Fig. 2, B to D), indicating that the
region spanning amino acids 420 to 587 is important for cohesin
binding. Convincingly, amino acids 401 to 587 were capable of
pulling down the cohesin complex (Fig. 2E). These data indicate that
ASXL1 and cohesin form a complex in the nucleus, and the amino
acid 401 to 587 region of ASXL1 mediates its interaction with the
cohesin complex.F l
ag
N
LS
A
B C
D E
ASXL1
Full length (FL)
aa 1–1010
aa 1–587
aa 1–420
aa 401–587
SMC1A
SMC3
RAD21
Flag
IB
Input IP:Flag
V
ec
V
ec
aa
 1
–1
01
0
aa
 1
–1
01
0
185
115
185
115
80
70
185
115
kD
SMC1A
SMC3
RAD21
Flag
Input IP:Flag
V
ec
V
ec
aa
 1
–5
87
aa
 1
–5
87
IB
185
115
185
115
80
70
80
70
kD
IB
Input IP:Flag
V
ec
V
ec
aa
 1
–4
20
aa
 1
–4
20
SMC1A
SMC3
RAD21
Flag
185
115
185
115
80
70
50
kD
SMC1A
SMC3
RAD21
Flag
Input IP:Flag
IB
V
ec
V
ec
aa
 4
01
–5
87
aa
 4
01
–5
87
185
115
185
115
80
70
30
kD
Fig. 2. Mapping the region of ASXL1 that mediates its binding to the cohesin complex. (A) Schematic diagram of the full-length (FL) ASXL1 and the truncated
variants of Asxl1 [amino acids (aa) 1 to 1010, 1 to 420, 1 to 587, and 401 to 587]. Binding affinity was determined by the pull-down efficiency of IP with anti-FLAG and
Western blotting with cohesin antibodies. NLS, nuclear localization signal. (B to E) Western blotting analysis of nuclear fractions and anti-FLAG immunoprecipitates from
pcDNA3.1+, or each truncated ASXL1 transfected HEK293T cells using antibodies against FLAG, SMC1A, SMC3, or RAD21.3 of 11
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the normal cell morphology and telophase
chromatin disjunction
Cohesin complex proteins embrace sister chromatids by forming a
ring-like structure; the defective function of any of the core cohesin
proteins disrupts the sister chromatid separation (32, 33). Myeloid
cells with depleted Asxl1 exhibit a specific dysplastic feature as a
pseudo–Pelget-Hüet anomaly (11). Examination of the peripheral
blood (PB) smear and BM of Asxl1+/− and Asxl1−/− mice revealed
an increased frequency of cells with nuclear bridging and prominent
disrupted sister chromatid separation inmyeloid cells (Fig. 3, A and B,
and fig. S2A). Consistently, significantly higher frequencies of cells
with nuclear bridging and impaired telophase chromatid disjunction
were observed, such as Asxl1+/− and Asxl1−/− cultures from Lin−cKit+
(LK) cells in the presence of a cocktail of growth factors including stem
cell factor (SCF), interleukin-3 (IL-3), macrophage colony-stimulating
factor, and thrombopoietin (Fig. 3, C and D).
To determine whether the increased frequency of cells with dis-
rupted chromatin disjunction is a direct consequence of Asxl1 loss,
we transfected human ASXL1-specific short hairpin RNA (shRNA-
hASXL1) and/or mouse Asxl1 (mAsxl1) complementary DNA
(cDNA) into HeLa cells stably expressing green fluorescent protein
(GFP)–H2B (HeLaGFP-H2B). ThemRNA levels of hASXL1 andmAsxl1
were determined by quantitative polymerase chain reaction (qPCR)
with primers specific for hASXL1 andmAsxl1, respectively. Transduc-
tion of shRNA-hASXL1 successfully decreased the expression of
hASXL1 mRNA by more than 40% but did not interfere with the ex-
pression of mAsxl1 (fig. S2B). Fluorescence microscopy was used to
quantify the morphology of the cells with or without bridging in the
nuclear. Knockdown (KD) of hASXL1 induced a markedly higher fre-
quency of dysplastic nuclear bridging cells (Fig. 3E and fig. S2C), and
reintroducing mASXL1 significantly reduced the frequency of cells
with premature sister chromatid separation (Fig. 3E and fig. S2C).
A parallel study was carried out to knock down SMC1A or RAD21
inHeLaGFP-H2B cells. SMC1AKDresulted in a decreased expression of
RAD21 and vice versa (fig. S2, D to F). This finding is consistent with
those of previous studies by other groups using different cell systems
that the protein levels of subunits of the cohesin complex are reduced
upon depletion of other subunits of the complex, probably because of
degradation (34–36). Consistently, both SMC1A and RAD21 KD led
to higher frequency of cells with nuclear bridging in HeLa cells (Fig. 3,
F and G). However, Western blot analysis showed that the levels of
SMC1A, SMC3, and RAD21 proteins are comparable in WT and
Asxl1−/− LK cells (fig. S2G). These results indicate that ASXL1,
SMC1A, and RAD21 are required for the maintenance of normal cell
morphology. Asxl1 loss–mediated cell bridging and premature chro-
matid separation are likely associated with an impaired cohesion
function rather than dysregulating SMC1A or RAD21 expression.
To further determine whether ASXL1 maintains normal cell mor-
phology through its interaction with the cohesin complex, we dis-
rupted cohesin/ASXL1 interaction by expressing ASXL1 amino acids
401 to 587, the cohesin binding region of ASXL1 in HeLaGFP-H2B
cells (Fig. 3H), and measured the frequency of cells with nuclear
bridging. Expression of ASXL1 amino acids 401 to 587 markedly
increased the frequency of cells containing premature sister chroma-
tid separation compared to cells expressing full-length ASXL1 or
vector control (Fig. 3I). This effect is presumably mediated by its dis-
ruption of the interaction between the endogenous WT ASXL1 and
cohesin. These results indicate that ASXL1 is critical for the functionLi et al. Sci. Adv. 2017;3 : e1601602 20 January 2017of the cohesin complex to maintain normal cellular function dur-
ing mitosis.
Asxl1 loss decreases the genomic occupancy of cohesin
in LK cells
The cohesin complex binds to the genomic DNA sequence and reg-
ulates gene expression (37–39). To examine whether the genomic
binding sites of ASXL1 and the cohesin proteins overlap, we next
performed ChIP-seq using WT and Asxl1−/− BM LK cells, as well
as antibodies against ASXL1, RAD21, and SMC1A. The genomic
binding sites of ASXL1, SMC1A, and RAD21 significantly overlap
(Fig. 4A). The percent binding cases at promoter regions for each
of the three proteins are 93.45% (ASXL1), 42.61% (SMC1A), and
40.39% (RAD21), respectively. This result further confirmed the as-
sociation of ASXL1 with the cohesin complex on the genome. Anal-
ysis of the genomic features showed that the ASXL1/SMC1A/RAD21
overlapping binding sites were enriched at promoter regions (93%),
whereas 5 and 2% of these sites were located at the gene body and
intergenic regions, respectively (Fig. 4B).
Comparison of the ChIP-seq peaks in WT and Asxl1−/− cells
showed that loss of Asxl1 markedly reduced cohesin occupancy on the
genome (based on the SMC1A and RAD21 peaks; Fig. 4, C and D).
Deletion ofAsxl1 reduced SMC1A and RAD21 overlapping peaks by
35% (Fig. 4D). Note that the DNA sequence recognized by SMC1A
or RAD21 (similar to the CTCF DNA binding sequence) remained
unchanged regardless of the presence or absence of ASXL1 (Fig. 4E).
These results suggest a role of ASXL1 in stabilizing, but not recruit-
ing, RAD21 and SMC1A onto the genome.
ASXL1 regulates gene expression via the cohesin complex
It has been reported that loss ofAsxl1 alters gene expression in LK cells
(11, 12). To determine whether alterations in the genomic binding sites
ofASXL1, SMC1A, andRAD21 are correlatedwith the changes of gene
expression inAsxl1−/− LK cells, we performed an integrated analysis of
ChIP-seq data with RNA sequencing (RNA-seq) data by focusing on
the ~3000 genes with ASXL1/RAD21/SMC1A overlapping peaks in
the promoter regions in WT LK cells. Among the ~1400 genes with
RAD21/SMC1A overlapping peaks in both WT and Asxl1−/− LK cells,
9.3 and 4.4% were significantly up-regulated and down-regulated, re-
spectively, in Asxl1−/− LK cells compared to WT cells (Fig. 5A). Of the
~1600 geneswith loss ofRAD21 and/or SMC1Aoccupancy inAsxl1−/−
LK cells, 14.9 and 4.1% of genes were significantly up-regulated and
down-regulated, respectively, in Asxl1−/− LK cells compared to WT
cells (Fig. 5B). Gene ontology (GO) analysis of these up-regulated
genes revealed associations with cell differentiation, regulation of
programmed cell death, myeloid differentiation, RNA polymerase II
activating transcription factor (TF) binding, and negative regulation
of gene expression (Fig. 5C). In contrast, the down-regulated genes
were associated with positive regulation of metabolic process,
transcription from RNA polymerase II promoter, regulation of cell
death, regulation of cell differentiation, and positive regulation of cell
proliferation (Fig. 5D). An enrichmentmapwas used for visualizing the
networks of these GO terms enriched with up-regulated and down-
regulated genes in Asxl1−/− LK cells (fig. S3). We identified a set of
up-regulated genes that are enriched in the biological process termed
“regulation of programmed cell death” between Asxl1−/− andWT cells,
such as Atf4, Klf4, and Btg1. Up-regulated ATF4 has been reported to
induce the transcriptional initiation of the apoptosis-related chop gene
(40). In addition, among the down-regulated genes in Asxl1−/− relative4 of 11
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Fig. 3. Loss of Asxl1 leads to premature sister chromatid separation in cells. (A and B) The myeloid cells with premature sister chromatid separation are frequently
seen in PB smears (A) and BM (B) of Asxl1+/− and Asxl1−/− mice with MDS. Red arrows indicate the abnormal nuclear bridging. Scale bars, 5 mm (A) and 10 mm (B). (C and
D) Representative cells with premature sister chromatid separation in cultured WT, Asxl1+/−, and Asxl1−/− LK cells. Red arrows indicate the premature sister chromatid
separation. The frequency of cells with premature sister chromatid separation is shown in (C). Y axis shows the percentage of cells with premature sister chromatid
separation within all binucleated cells. Data are represented as means ± SEM from three independent experiments. ***P < 0.001 and **P < 0.01. Scale bars, 5 mm. (E) The
frequency of cells with premature sister chromatid separation in the HeLaGFP-H2B cells with hASXL1 KD and hASXL1 KD plus mAsxl1 rescues. KD of ASXL1 leads to
increased frequency of cells with premature sister chromatid separation in HeLaGFP-H2B cells. Reintroducing full-length mAsxl1 rescued the premature sister chromatid
separation in HeLa cells with ASXL1 KD. Data are represented as means ± SEM from three independent experiments. ***P < 0.001 and **P < 0.01. (F and G) SMC1A or
RAD21 KD leads to premature sister chromatid separation in HeLaGFP-H2B cells. Representative photomicrographs show the cells with premature sister chromatid sep-
aration, as indicated by red arrowheads (G). The frequency of cells with premature sister chromatid separation is shown in (F). Y axis shows the percentage of cells with
premature sister chromatid separation within all binucleated cells. Data are represented as means ± SEM from three independent experiments. ***P < 0.001 and **P <
0.01. Scale bars, 5 mm. (H) Western blotting shows the expression of full-length ASXL1 and ASXL1 amino acids 401 to 587 in HeLaGFP-H2B cells transfected with vector
only, full-length ASXL1, or ASXL1 amino acids 401 to 587. b-Actin serves as loading control. (I and J) ASXL1 amino acids 401 to 587 induce chromatin bridging in
HeLaGFP-H2B cells. Quantification of the frequency of cells with premature sister chromatid separation in HeLaGFP-H2B cells transfected with pcDNA3.1+, full-length ASXL1,
or ASXL1 amino acids 401 to 587 (J). Data are represented as means ± SEM from three independent experiments. **P < 0.01 for ASXL1 amino acids 401 to 587 fragment
versus pcDNA3.1+ or full-length ASXL1. Red arrows indicate the premature sister chromatid separation. Scale bars, 5 mm.Li et al. Sci. Adv. 2017;3 : e1601602 20 January 2017 5 of 11
SC I ENCE ADVANCES | R E S EARCH ART I C L EtoWT cells, we identified multiple genes that have a positive impact on
cell proliferation, such asMyc, Nfya, and Slc. Patients with gene muta-
tions of ASXL1 and/or the cohesin complex are found in all forms of
myeloid malignancies, including MDS, MDS/MPN, and AML. These
cellular phenotypes might be associated with changes of multiple
genes. Further studies are warranted to validate these data in human
primary cells. Two recent studies using Stag2 KD or Smc3 deletion
demonstrated that cohesin proteins are required for the maintenance
of normal gene expression in HSCs, and deletion of either Stag2 or
Smc3 altered transcriptional output, leading to differentiation skewing
of HSCs (35, 41).
A number of ASXL1/SMC1A/RAD21 target genes inAsxl1−/− LK
cells are dysregulated, which are implicated in myeloid cell develop-
ment and/or the pathogenesis of myeloid malignancies (Fig. 5E). ForLi et al. Sci. Adv. 2017;3 : e1601602 20 January 2017example, ASXL1, SMC1A, and RAD21 co-occupy Cbfb and Fus gene
promoters in LK cells (Fig. 5, F and G). Asxl1 loss reduced both
SMC1A and RAD21 occupancy at Cbfb and Fus promoters. qPCR
confirmed the alteration of the gene expression levels, including
Cbfb, Fus, and Stat3 (Fig. 5H). These data suggest that ASXL1 acts
in concert with cohesin to regulate their target gene expression and
that loss of Asxl1 decreases cohesin occupancy, leading to alterations
in gene expression.DISCUSSION
High frequencies of ASXL1 mutations occur in multiple forms of
myeloid malignancies, and ASXL1 mutations are associated with
poor prognosis, suggesting a driving role of ASXL1 mutations inA
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bars. (E) Heatmap of differentially expressed genes of myeloid malignancy relevance within Asxl1/SMC1/RAD21 overlapping loci in Asxl1−/− LK cells. (F and G) Genome
browser tracks of the Cbfb and Fus locus with overlapping ASXL1, SMC1A, or RAD21 peaks. (H) Relative RNA level of Cbfb, Fus, and Stat3 in LK cells as determined by qPCR.
Data are represented as means ± SEM from three independent experiments. ***P < 0.001 and **P < 0.01.Li et al. Sci. Adv. 2017;3 : e1601602 20 January 2017 7 of 11
SC I ENCE ADVANCES | R E S EARCH ART I C L Ethe progression of disease (1, 3, 4, 42–45). However, the mechanisms
by which ASXL1 loss leads to myeloid malignancy remain to be elu-
cidated. ASXL1 has been shown to interact with various proteins to
exert its regulatory function. ASXL1 recruits polycomb repressive
complex 2 (PRC2) to exert its transcriptional repression through
H3K27me3 (46, 47). ASXL1 has also been shown to interact with
the retinoid acid receptor TF (48). Identification of the key ASXL1
binding partners would facilitate the investigation of mechanisms
through which ASXL1 mediates its tumor-suppressive functions.
Our protein purification and LC-MS/MS analyses identified cohesin
proteins (including RAD21, SMC1A, SMC3, and STAG1/STAG2) as
the major binding partners of ASXL1. Similar to ASXL1, cohesin genes
are frequently mutated in multiple forms of myeloid malignancies
(16, 30, 49). Although ASXL1 and cohesin form a big protein complex,
the ASXL1mutations and cohesin gene mutations are not strictly mu-
tually exclusive in these patients (16, 28), indicating that ASXL1 and
the cohesin complex have both overlapping and unique functions.
The cohesin complex has been shown to be critical for sister chro-
matid cohesion (23, 33) and gene expression regulation (37–39). Loss
of any cohesin protein leads to premature sister chromatid separa-
tion (32, 50). Similar to cohesin loss, we show that Asxl1 loss also
causes disruption of telophase chromatin disjunction, indicating that
ASXL1 in concert with cohesin participates in this biological process.
Furthermore, disruption of ASXL1 and the cohesin complex inter-
action by ASXL1aa401–587 expression, the region of ASXL1mediating
cohesin complex binding, impaired telophase chromatin separation.
These results further demonstrate that ASXL1 is essential for the in-
tegral function of the cohesin complex in the maintenance of chro-
matin separation during cell division.
We and others have reported thatAsxl1 loss leads toMDS-like dis-
ease inmice (11, 12). Here, we provide further evidence thatAsxl1 loss
increased frequencies of dysplastic myeloid cells with disrupted chro-
matin separation in the PB and BM. Recently, two independent
groups reported that cohesin loss leads to the development of myeloid
malignancies in mice (35, 41). Here, we show that ASXL1 binds to the
cohesin complex and plays an essential role in maintaining normal
chromatin separation during cell division, suggesting an overlapping
molecular mechanism that underlies the pathogenesis of the myeloid
disorders driven by alterations of ASXL1 or cohesin genes.
In addition tomaintaining normal sister chromatid separation, the
cohesin complex has also been shown to be important inmultiple pro-
cesses regulating transcription and gene expression (26, 51–54). We
also explored whether the occupancy of ASXL1 and cohesin overlaps
on the genome inWTLK cells and whether the deletion ofAsxl1 alters
the occupancies of cohesin on the genome. Analysis of the ChIP-seq
data of ASXL1, RAD21, and SMC1A in WT and Asxl1−/− LK cells
showed significant overlapping in ASXL1/SMC1A/RAD21 binding
sites, which are enriched at promoter regions (93%). Furthermore,
Asxl1 deletion reduced the occupancy of cohesin on the genome.
TheDatabase for Annotation, Visualization, and IntegratedDiscovery
functional analysis of the up-regulated ASXL1 target genes revealed
associations with cell differentiation, regulation of programmed cell
death, myeloid differentiation, RNA polymerase II activating TF
binding, and negative regulation of gene expression. Deletion ofAsxl1
in LK cells dysregulated a number of ASXL1/SMC1A/RAD21 com-
mon target genes, including Stat3, Cbfb, and Fus, which are impli-
cated in myeloid cell development and/or the pathogenesis of
myeloid malignancies. These results suggest a role of ASXL1 in sta-
bilizing, but not recruiting, RAD21 and SMC1A onto the genome.Li et al. Sci. Adv. 2017;3 : e1601602 20 January 2017Cohesin proteins have been shown to be important for chromatin
topology and facilitate enhancer-promoter looping to regulate gene
transcription (55, 56). Future study is warranted to investigatewhether
ASXL1 mutations interfere with normal long-range chromosome in-
teractions, altering gene expression and leading to the pathogenesis of
myeloid malignancies.
In this study, we have identified a novel biological link that under-
lies the similar clinical features in MDS that are mediated by muta-
tions in either ASXL1 or its major partners in cohesin genes. We also
have shown that the ASXL1-cohesin interaction on the genome is
important for regulating gene transcription in hematopoietic cells,
establishing a novel mechanism of gene regulation by ASXL1 via
the cohesin complex. Our data reinforce the view that ASXL1 has
multifaceted functions in gene regulation by assembling epigenetic
regulators and TFs to specific genomic loci.MATERIALS AND METHODS
Mouse models
Asxl1+/− mice were generated as previously reported (11). Here, all
mice were bred on a C57BL/6 genetic background. All animal
experiments were conducted in accordance with the Guide for the
Care and Use of Laboratory Animals. All animal protocols were ap-
proved by the University of Miami Institutional Animal Care and
Use Committee.
Plasmid constructs and shRNA
The cDNA of full-length mAsxl1 and its truncated variants (amino
acids 1 to 1010, 1 to 587, 1 to 420, and 401 to 587) were tagged with
3×FLAG and engineered into pcDNA3.1+ (Invitrogen). The shRNA
plasmids of ASXL1 (TG306527), SMC1A (TL513033), and RAD21
(TL501846) were purchased from OriGene.
Cell culture, retroviral transduction, and
morphological analysis
HEK293T, HeLa, and HeLaGFP-H2B cells (57) were cultured and trans-
fected with full-length Asxl1 and its truncation variant plasmids using
Calcium Phosphate Transfection Kit (Invitrogen). The freshly isolated
LK cells from fetal liver were cultured in RPMI 1640 medium (Gibco)
supplemented with 10% fetal bovine serum, SCF (100 ng/ml), and
IL-3 (10 ng/ml) (PeproTech). For morphological analysis, PB was
collected and smeared for May-Grünwald-Giemsa staining. Mor-
phological analysis and cell differentiation of BM and fetal liver
LK cells were performed on cytospins (5 × 105 cells per sample),
followed by May-Grünwald-Giemsa staining. HeLaGFP-H2B cells
were cultured on ultrathin glass coverslips. Images were acquired
on a DeltaVision deconvolution microscope (Applied Precision)
equipped with a 60× or 100× objective. All images were obtained
and processed identically.
IP assay and LC-MS/MS
IP was performed using nuclear fraction buffer and washed with IP
buffer [20 mM tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100,
5mMEDTA, 2mM sodium orthovanadate, 1mMphenylmethylsul-
fonyl fluoride, 2 mM NaF, and protease inhibitor cocktail (Roche)]
for four times. For FLAG-tagged ASXL1, the IPs were eluted with
3×FLAG peptide (100 ng/ml; Sigma-Aldrich, F4799) in phosphate-
buffered saline for 30 min at room temperature. All the IPs were per-
formed with nuclear extraction.8 of 11
SC I ENCE ADVANCES | R E S EARCH ART I C L EFLAG-ASXL1was immunoprecipitated from the nuclear extracts
with anti-FLAG antibody–conjugated beads (Sigma-Aldrich), and
the associated proteins were eluted from the beads by FLAG pep-
tides. The eluates were then resolved on NuPAGE 4 to 12% Bis-Tris
Gel (Invitrogen) followed by Coomassie brilliant blue staining, and
lanes were excised for MS analysis by the Taplin Biological Mass
Spectrometry Facility (Harvard Medical School).
qPCR analysis
Total RNAwas isolated with TRIzol reagent (Invitrogen). The cDNA
was synthesized using QuantiTect Reverse Transcription Kit (Qiagen).
qPCRwas performed using anABI StepOnePlus with Fast SYBRGreen
Master Mix (Applied Biosystems). PCR amplifications were performed
in triplicate for each gene of interest along with parallel measurements
of b-actin. The primers used for the amplification of each gene are
shown in table S2.
ChIP assays
BM LK cells were fixed with 1% formaldehyde for 15 min and
quenchedwith 0.125Mglycine. Chromatinwas isolated and sonicated
to an average length of 300 to 500 bp. Genomic DNA regions of in-
terest were isolated using antibodies against ASXL1 (Santa Cruz Bio-
technology, sc-85283), SMC1A (Abcam, ab133643), and RAD21
(Abcam, ab154769). Illumina sequencing libraries were prepared
and sequenced on a NextSeq 500.
Raw sequence reads from the FASTQ files of the six ChIP-seq
samples were trimmedusing sickle (https://github.com/najoshi/sickle)
(58) with the Phred quality score threshold of 20 bases and the length
threshold of 50 bases. Next, the trimmed reads were mapped against
the mouse reference genome mm9 using bowtie 1.1.2 (59), allowing
two mismatches. The promoter region was defined as the region 1000 bp
upstream and 1000 bp downstream of the first transcription start site of
a transcript cluster constructed using UCSC (University of California,
Santa Cruz) known gene annotation of mm9. The uniquely mapped
reads were counted in each promoter region. These counts of all
samples were tabulated, and the differential bindings of ASXL1,
SMC1A, and RADad21 in the promoter regions were tested using
the Poisson test. The Benjamini-Hochberg procedure (60) was used
to correct for multiple hypothesis testing. The differentially bound
promoters were identified with a false discovery rate (FDR) cutoff of
0.05. To evaluate and identify statistical significance on the association
between SMC1A, RAD21, andASXL1 binding profiles inWTcells, we
applied a hypergeometric test and calculated P values (table S3).
Specifically, the CTCF-like motifs were discovered on the basis of
their high occurrences with significant E values, in the sequences
where peaks were identified on each of the four ChIP-seq data sets:
SMC1A in WT cells (3.3 × 10−61), RAD21 in WT cells (2 × 10−145),
SMC1A in Asxl1−/− cells (7.1 × 10−146), and RAD21 in Asxl1−/− cells
(2.9 × 10−183). The matches between these motifs and the known
CTCF DNA binding motif were also highly significant, measured
against the likelihood of the same matches by random sequences,
with all significant FDR-adjusted P values for SMC1A in WT cells
(4.12 × 10−13), RAD21 in WT cells (1.35 × 10−10), SMC1A in
Asxl1−/− cells (2.05 × 10−13), andRAD21 inAsxl1−/− cells (2.64 × 10−9).
RNA-seq and analysis
Total RNAwas isolated fromBMLKcells ofWTorAsxl1−/−mice (18-
to 21-day-old mice) following standard protocol with TRIzol reagent
(Invitrogen) followed by mRNA library preparation with the TruSeqLi et al. Sci. Adv. 2017;3 : e1601602 20 January 2017strand-specific mRNA sample preparation system (Illumina). The
library was sequenced (PE100bp) using the Illumina HiSeq 2500.
Raw sequence reads from the FASTQ files of the four RNA-seq
samples were mapped against the mouse reference genome mm9
using STAR2.3.1t with the default parameters (61). Only the uniquely
mapped reads were used to count against the UCSC known gene an-
notation of mm9 to calculate the numbers of reads per gene. The
counts of all samples were tabulated, then analyzed using DESeq
(62) for normalization and identification of differentially expressed
genes between the control and knockout samples using a standard
workflow, as previously described (63, 64). The Benjamini-Hochberg
procedure (61) was used to correct formultiple hypothesis testing. The
differentially expressed genes were identified with an FDR cutoff of
0.05. GO analysis of differentially expressed genes of all comparisons
was performed using Fisher’s exact test.
Statistical analysis
Differences between experimental groups were determined by Stu-
dent’s t test or analysis of variance (ANOVA) followed by Newman-
Keuls multiple comparison tests, as appropriate.SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/3/1/e1601602/DC1
fig. S1. ASXL1 forms a complex with the cohesin complex.
fig. S2. Reintroducing mAsxl1 rescued the premature sister chromatid separation in HeLa cells
with ASXL1 KD.
fig. S3. Enrichment map was used for visualizing the network of selected GO terms enriched
with up-regulated and down-regulated genes in Asxl1−/− LK cells.
table S1. List of ASXL1 interaction proteins identified by MS in HEK293T cells transfected with
FLAG-ASXL1.
table S2. qPCR primer sequences.
table S3. Statistical evidence for binding between SMC1A, RAD21, and ASXL1.REFERENCES AND NOTES
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